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A series of amine derivatives of 5-aromatic imidazolidine-4-ones (7e19), representing three subgroups:
piperazine derivatives of 5-arylideneimidazolones (7e13), piperazine derivatives of 5-
arylideneimidazolidine-2,4-dione (14e16) and primary amines of 5-naphthyl-5-methylimidazolidine-
2,4-diones (17e19), was evaluated for their ability to improve antibiotics effectiveness in two strains of
Gram-positive Staphylococcus aureus: ATCC 25923 (a reference strain) and MRSA (methicillin resistant S.
aureus) HEMSA 5 (a resistant clinical isolate). The latter compounds (17e19) were obtained by 4-step
synthesis using Bucherer-Bergs condensation, two-phase bromoalkylation and Gabriel reactions. The
naphthalen derivative: (Z)-5-(naphthalen-2-ylmethylene)-2-(piperazin-1-yl)-3H-imidazol-4(5H)-one
(10) was the most potent in combination with b-lactam antibiotics and ciproﬂoxacin against the resistant
strain. The high potency to increase efﬁcacy of oxacillin was noted for (Z)-5-(anthracen-10-ylmethylene)-
2-(piperazin-1-yl)-3H-imidazol-4(5H)one (12) too. In order to explain the mechanism of action of the
compounds 10 and 12, docking studies with the use of crystal structures of a penicillin binding protein
(PBP2a) and MecR1 were carried out. Their outcomes suggested that the most probable mechanism of
action of the active compounds is the interaction with MecR1. Molecular dynamic experiments per-
formed for the active compounds and compound 13 (structurally similar to 12) supported this hypothesis
and provided possible explanation of activity dependencies of the tested compounds in terms of the
restoration of antibiotic efﬁcacy in S. aureus MRSA HEMSA 5.
© 2015 Elsevier Masson SAS. All rights reserved.1. Introduction
Staphylococcus aureus (S. aureus) is a Gram positive bacterium
that can cause a range of illnesses, fromminor skin infections, such
as pimples, impetigo, boils, folliculitis, scalded skin syndrome, and
abscesses, to life-threatening diseases such as pneumonia,served.meningitis, osteomyelitis, endocarditis, toxic shock syndrome (TSS),
bacteremia, and sepsis. Its incidence ranges from skin, soft tissue,
respiratory, bone, joint, endovascular to wound infections [1e3].
Methicillin-resistant S. aureus (MRSA) has caused serious
problems in the use of the major classes of antibiotics in common
use e cephalosporins, penicillins, carbapenems, quinolones and
aminoglycosides [4] and hence it is in actuality a multi-drug
resistant (MDR) bacterium. The resistance of MRSA strains to b-
lactam antibiotics is well understood and is caused by the synthesis
of a modiﬁed penicillin binding protein (PBP) named PBP2a. PBPs
are membrane-bound enzymes that participate in the biosynthesis
A. Matys et al. / European Journal of Medicinal Chemistry 101 (2015) 313e325314of the bacterial cell wall [5]: they catalyze the transpeptidation
reaction that is necessary for cross-linkage of peptidoglycan chains
[6]. Unmodiﬁed PBP is the target for b-lactam antibiotics e binding
of a b-lactam antibiotic to the active center of the PBP protein in-
activates the enzyme and results in bacterial growth inhibition due
to the inhibition of cell wall synthesis. In turn, the modiﬁed PBP
protein (PBP2a) present in MRSA strains displays much lower af-
ﬁnity to b-lactam antibiotics that renders theMRSA resistant to this
group of antibiotics. The modiﬁed PBP2 protein of MRSA strains is
due to the acquisition of a mobile genetic element from an un-
known bacterial source, SCCmec (Staphylococcal Cassette Chro-
mosome) which contains themecA gene that encodes the modiﬁed
PBP protein (PBP2a). Upon the acquisition of SCCmec, MSSA
(methicillin-sensitive S. aureus) changes to MRSA. The SCCmec
cassette can be ejected from the MRSA chromosome when the
MRSA organism is placed under stress to another antibiotic [7] and
converts the MRSA to MSSA phenotype [8]. The expression of the
mecA gene is regulated by two proteins: MecI (a repressor protein)
and MecR1 (a signal transducer protein). When MecI binds to the
promoter region of mecA, the transcription of mecA is repressed.
The active site centre of MecR1 penicillin binding domain is the
catalytic serine residue at the beginning of helix a3, Ser391. If
MecR1 detects b-lactam antibiotics in the extracellular space via
MecR1 penicillin binding domain, it becomes acylated at its active-
site serine residue. Thus, when b-lactam antibiotics bind to MecR1,
the polypeptide having protease activity is released fromMecR1 to
degrade MecI, resulting in increased transcription of mecA, and
consequently a higher level of PBP2a is reached [9].
S. aureushas also anumberof efﬂuxpumps including those of the
MF family (NorA,Mef, Tet; the efﬂuxpumpQac is plasmidmediated)
and the ABC family (Msr(A)) that are able to extrude antibiotics
outside the cell, thus reducing the efﬁcacy of the drugs [10].
SinceMRSA is aworldwide problem in clinical medicine, there is
a need for developing new therapeutic agents against this bacte-
rium. One of the strategies is to search for adjuvants that enhance
the action of antibiotics and may thus restore the efﬁcacy of ther-
apeutically inactive agents. The combination of a resistance inhib-
itor with an antibiotic has already proven its efﬁcacy with the
clavulanic acid (inhibitor of beta-lactamase)/amoxicillin associa-
tion [11]. Lines of evidence indicated several chemical families
[11e16] of inhibitors of the S. aureus efﬂux pumps, mainly the NorA
efﬂux pump (Fig 1) [11].
On the other hand, the imidazolidine-4-one pattern, that is in
the area of interest of our research group, gives great opportunity
for chemical modiﬁcations resulting in various biological actions,
among others: GPCR-ligand properties [17,18], hypotensive,1
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Fig. 1. Chemical families of inhibitors of MDR in S. aureus: derivatives of 2-(4-propoxyph
N-cinnamoylphenalkylamide derivatives (4) [9]; dihydronaphthalene inhibitors of the NorAantiarrhythmic or anticonvulsant activities [19,20] as well as anti-
bacterial, antifungal [21,22] or anticancer properties [23]. Our
recent studies indicated moderate properties of chemosensitizers
against multi-drug resistant E. aerogenes of several hydantoin de-
rivatives (imidazolidine-2,4-dione) [24,25] and modulators of
cancer efﬂux proteins of 5-arylideneimidazolones [26].
Therefore, the aim of this study was to test a series of imidazoli-
dine-4-one derivatives, representing three subgroups A-C (Table 1),
including the compounds that proved active in the previous assays
against multi-drug resistant E. aerogenes [25] and the new ones, in
terms of their ability to enhance the action of a b-lactamantibiotics in
S. aureus. The synthesis of the new compounds and microbiological
assays for the whole population are described herein. One of the
compounds that displayed high activity against MRSAwas also eval-
uated for cytotoxicity in preparation for further pre-clinical studies.
In order to verify the mechanism of action of the tested com-
pounds, a molecular modeling study was carried out. The interac-
tionwith the proteins involved inMRSA b-lactam resistance (PBP2a
and MecR1) was examined by docking and molecular dynamic
experiments.
2. Results and discussion
2.1. Synthesis
A series of the compounds 7e14were designed and synthesized
in theDepartmentof TechnologyandBiotechnologyofDrugs JU-MC.
Before synthesis, a search for their structures in the program Sci-
Finder was performed. Syntheses of the compounds 7e14 are
described elsewhere [25e27]. In order to obtain the compounds 15
and 16, the 4-step synthetic path was carried out (Scheme 1).
TheKnoevenagel condensationwas theﬁrst step inwhichhydantoin
was condensed with aromatic aldehyde giving 5-
arylideneimidazolidine-2,4-dione (20, 21). In the next step, the
products of theKnoevenagel condensationwere combinedwith2,3-
epoxy-1-propanol in the Mitsunobu reaction giving the N3-oxiran-
5-arylideneimidazolidine-2,4-dione intermediates (22, 23). In the
third step, which was N-alkylation, the compounds 22 and 23were
melted with 1-acetylpiperazine using microwave irradiation (22)
and an oil bath (23). The last stepwas an N-acetyl deprotection of 3-
(3-(4-acetylpiperazin-1-yl)-2-hydroxypropyl)-5-
arylideneimidazolidine-2,4-dione (24, 25) producing the hydro-
chloride formof theﬁnal deprotectedpiperazinederivatives (15,16).
The compounds 17e19 were obtained by 4-step synthesis ac-
cording to Scheme 2. In the ﬁrst step, Bucherer-Bergs cyclic
condensation was performed with 2-naphthylacetophenone toO
O
O
NH3C
CH3
3
6
O
N
O
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O
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enyl)quinoline (1) [10], citral amide derivatives (2) [11]; chalcone inhibitors (3) [12];
efﬂux pump in S. aureus (5) [13]; piperine analogs (6) [14].
Table 1
Structure of tested derivatives of imidazolidine.
Cpd Group Ar Cpd Group R1 Amine n
7 A 14 B 4-OCH3 e
8 A 15 B 4-Cl e
9 A 16 B 2,4-diCl e
10 A 17 C e e 1
11 A 18 C e e 2
12 A 19 C e e 3
13 A
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compound 26 was alkylated at position 3 using suitable dibro-
moalkanes to give bromoalkyl (C3eC5) derivatives 27e29, which
were used as alkylating agents to obtain (5-methyl-5-(naphtha-
lene-1-yl)imidazolidin-2,4-dione-3-yl)alkyl derivatives of phthali-
mide (30e32). The pure compounds 17e19 were obtained by
reaction of the phthalimide derivatives 30e32 with hydrazine.2.2. Microbiological assays
The whole series of compounds (7e19) were tested inScheme 1. Synthesis route fomicrobiological assays [28] for their ability to increase oxacillin
effectiveness in two strains of S. aureus: a reference strain ATCC
25923 and a clinical isolate MRSA HEMSA 5. Selected representa-
tives of each chemical group were also tested with other b-lactam
antibiotics: cloxacillin (resistant to b-lactamases) and ampicillin
(susceptible to b-lactamases) in combination with sulbactam (b-
lactamase inhibitor) as well as ﬂuoroquinolones (ciproﬂoxacin) and
aminoglycosides (neomycin) using the same strains.2.2.1. Direct antibacterial activity
In the ﬁrst step of the microbiological assays, direct antibacterialr compounds 15 and 16.
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Scheme 2. Synthesis route for compounds 17e19, n ¼ 3e5.
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centration (MIC) of the compounds 7e19 was determined for both
strains by the broth dilution method [28] (Table 2). The tested
compounds displayed varied direct antibacterial activities. Most of
the compounds did not inhibit growth of both S. aureus strains at
1 mM. The lowest MICs were observed for piperazine derivatives of
5-arylideneimidazolones 11 and 13. These compounds demon-
strated MIC values in the range of 1.9e15.6 mM in the reference
strain, whereas their MIC in MRSA HEMSA 5 was lower than those
of tested b-lactam and aminoglycoside antibiotics, in particular,
23e45-fold lower than that of oxacillin (15.6e31.3 mM, Table 2).2.2.2. Inﬂuence on MIC of antibiotics
In the next step of the microbiological assays, the compounds
7e19were tested for their ability to increase the activity of oxacillin
in the tested bacterial strains. The compounds were tested in the
concentrations not exceeding 1/4 of their MICs. Activity gains (A)
were calculated according to the equation presented in Table 3.
Most of the compounds had no impact on oxacillin activity. The
most active compound was 10, which decreased the MIC of
oxacillin 128-fold in the MRSA HEMSA 5 strain. Another active
compound (12) was able to reduce the MIC of oxacillin 64-fold in
the HEMSA 5 strain (Table 3). Since the corresponding reduction in
the reference strain in both of these cases was negligent, this
suggests that the modulation of bacterial resistance in the MRSATable 2
Direct antibacterial activity for compounds 7e19.
Group Compd
A 7
A 8
A 9
A 10
A 11
A 12
A 13
B 14
B 15
B 16
C 17
C 18
C 19
Ref Oxacillin
Cloxacillin
Ampicillin þ sulbactam
Ciproﬂoxacin
NeomycinHEMSA 5 strain by the compounds 10 and 12may involve proteins
responsible for b-lactam resistance in MRSA strains: PBP2a and
MecR1, the more so that 10 and 12were also active with another b-
lactam antibiotic cloxacillin (Table 4). This hypothesis was veriﬁed
by checking the ability of these compounds to reduce the MIC of
antibiotics which have a different mechanism of action: ﬂuo-
roquinolones (ciproﬂoxacin) and aminoglycosides (neomycin)
against S. aureusMRSA HEMSA 5 (Table 5). Here,12was completely
inactive, and 10 showedminor activity only in case of ciproﬂoxacin.
Apart from acting on bacterial gyrase, ciproﬂoxacin is also a sub-
strate of efﬂux pumps so the lack of substantial activity suggests
that the interaction of 10 and 12 with efﬂux pumps is rather un-
likely. The compound 12 was inactive in case of
ampicillin þ sulbactam, but this does not rule out the suggested
mechanism of action as ampicillin may be a too small molecule
compared to oxacillin and cloxacillin to exert the desired effect. It
may be also due to the fact that there are too many components in
this system (ampicillin, sulbactam, compound) so they compete
with each other in membrane transport.
Apart from 10 and 12, no compound had any statistically sig-
niﬁcant impact (4-fold) on oxacillin activity, whereas compounds
11 and 14 improved (8-fold) the action of cloxacillin against MRSA
HEMSA 5 (Table 4). The series of compounds (7e19) did not raise
the efﬁcacy of any tested antibiotics in the reference strain. Com-
pounds 10 and 11 caused a 2-fold reduction in the MIC of oxacillinS. aureus MRSA HEMSA 5 S. aureus ATCC 25923
MIC [mM] MIC [mM]
0.5 >1
>1 >1
1 >1
0.5 0.25
0.0313 0.0156
0.5 0.5
0.0156 0.0019
>1 >1
1 >1
>1 >1
>1 >1
>1 >1
1 >1
0.71 0.00047
0.16 0.00042
0.2 0.00054
0.014 0.00038
0.24 0.001
Table 4
Inﬂuence of selected compounds (8e14 and 17) on minimal inhibitory concentration (MIC) of other b-lactam antibiotics: cloxacillin and ampicillin þ sulbactam against
S. aureus MRSA HEMSA 5.
Group Cpd Cloxacillin Ampicillin þ sulbactam
Concentration of compound
[mM]
Reduction of
MIC
Numerical value of
reduction
Concentration of compound
[mM]
Reduction of
MIC
Numerical value of
reduction
A 8 0.5 No effect e 0.5 No effect e
A 9 0.25 No effect e 0.25 No effect e
A 10 0.125 256-fold From 315 mM to 1.23 mM 0.125 4-fold From 202 mM to 50.5 mM
A 11 0.0078 8-fold From 315 mM to 39.4 mM 0.0078 No effect e
A 12 0.125 8-fold From 315 mM to 39.4 mM 0.125 No effect e
A 13 0.0039 2-fold From 315 mM to 157.5 mM 0.0039 No effect e
B 14 0.5 8-fold From 315 mM to 39.4 mM 0.5 2-fold From 202 mM to 101 mM
C 17 0.5 No effect e 0.5 No effect e
Compounds 8e14 and 17 did not have any inﬂuence on minimal inhibitory concentration (MIC) of cloxacillin and ampicillin þ sulbactam against S. aureus ATCC 25923.
Table 5
Inﬂuence of selected compounds (8e14 and 17) on minimal inhibitory concentration (MIC) of ﬂuoroquinolones (ciproﬂoxacin) and aminoglycosides (neomycin) against
S. aureus MRSA HEMSA 5.
Group Cpd Ciproﬂoxacin Neomycin
Concentration of compound
[mM]
Reduction of
MIC
Numerical value of
reduction
Concentration of compound
[mM]
Reduction of
MIC
Numerical value of
reduction
A 8 0.5 No effect e 0.5 No effect e
A 9 0.25 No effect e 0.25 No effect e
A 10 0.125 4-fold From 15.1 mM to 3.77 mM 0.125 No effect e
A 11 0.0078 No effect e 0.0078 No effect e
A 12 0.125 No effect e 0.125 No effect e
A 13 0.0039 No effect e 0.0039 No effect e
B 14 0.5 2-fold From 15.1 mM to 7.55 mM 0.5 No effect e
C 17 0.5 No effect e 0.5 No effect e
Compounds 8e14 and 17 did not have any inﬂuence on minimal inhibitory concentration (MIC) of ciproﬂoxacin and neomycin against S. aureus ATCC 25923.
Table 3
Inﬂuence of compounds 7e19 on minimal inhibitory concentration (MIC) of oxacillin A ¼ MIC of antibiotic in absence of compound ð719ÞMIC of antibiotic in presence of compound ð719Þ.
Group Cpd S. aureus MRSA HEMSA 5 S. aureus ATCC 25923
Concentration of compound
[mM]
Reduction of
MIC
Numerical value of
reduction
Concentration of compound
[mM]
Reduction of
MIC
Numerical value of
reduction
A 7 0.125 No effect e 0.5 No effect e
A 8 0.5 No effect e 0.5 No effect e
A 9 0.25 No effect e 0.5 No effect e
A 10 0.125 128-fold From 710 mM to 5.55 mM 0.0625 2-fold From 0.47 mM to 0.23 mM
A 11 0.0078 No effect e 0.0039 2-fold From 0.47 mM to 0.23 mM
A 12 0.125 64-fold From 710 mM to 11.09 mM 0.125 2-fold From 0.47 mM to 0.23 mM
A 13 0.0039 No effect e 0.0005 No effect e
B 14 0.5 2-fold From 710 mM to 355 mM 0.5 No effect e
B 16 0.5 No effect e 0.5 No effect e
C 17 0.5 No effect e 0.5 No effect e
C 18 0.5 No effect e 0.5 No effect e
C 19 0.25 No effect e 0.5 No effect e
Table 6
Number of poses obtained for each compound in the procedure of docking into
crystal structures of PBP2a and MecR1 binding domain.
Cmd Number of 3D conformations Number of poses
obtained by docking
MecR1 PBP2a
7 3 2 0
8 8 9 5
9 4 4 2
10 3 1 0
11 3 0 0
12 6 10 3
13 6 7 3
14 6 6 6
15 2 2 0
16 2 3 0
17 1 1 1
18 1 1 2
19 1 2 1
Oxacillin 1 1 2
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it ﬁts within the method's inaccuracy range. Apart from compound
10, moderately increasing ciproﬂoxacin action, no compound had
impact neither on ﬂuoroquinolones nor aminoglycosides
(neomycin) effectiveness against MRSA HEMSA 5 (Table 5).
2.3. Molecular modeling
At ﬁrst, molecular docking experiments were performed to ﬁnd
out with which protein the tested compounds potentially interact
e all the tested compounds were docked into the crystal structures
of MecrR1 and PBP2a (Table 6). Next, with the use of molecular
dynamic simulations, differences in ability to restore the antibiotic
efﬁcacy against the resistant S. aureus strain of the selected com-
pounds were analyzed.
2.3.1. Docking results
Docking results revealed that all of the tested compounds were
Fig. 2. Interaction mode of 12 (a), 13 (b) and 10 (c) with MecR1 binding domain (complexes with the lowest docking score were selected). a) Amino acids that interact only with 12
are marked in blue; b) amino acids that interact only with 13 are marked in green; c) amino acids that interact only with 10 are marked in yellow; Ser391 is marked with red. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
A. Matys et al. / European Journal of Medicinal Chemistry 101 (2015) 313e325318much more successful in interacting with MecR1 than PBP2a as the
number of the obtained ligand-protein complexes wasmuch higher
in case of MecR1 in comparison to the modiﬁed PBP (Table 6). The
only compound for which the same number of ligand-protein
complexes was obtained in case of MecR1 and PBP2a was 14.
Compound 14 was also the one which caused 2-fold increase in
oxacillin activity. This increase is only minor and ﬁts in the
method's inaccuracy range.
As one of the active compounds (12) exhibits a very high
structural similarity to compound 13 (inactive in in vitro tests), a
careful analysis of the binding of 10, 12 and 13 to MecR1 was per-
formed. The docking studies revealed that these compounds bind
in slightly different orientation modes and interact with different
amino acids of MecR1. For each molecule, amino acids that inter-
acted exclusively with one of these three compounds were iden-
tiﬁed (Fig. 2).
2.3.1.1. Docking results for oxacillin and cloxacillin. The docking
studies were performed only for oxacillin and cloxacillin for two
reasons. First of all, oxacillin and cloxacillin were the only antibi-
otics whose efﬁcacy was substantially increased by the addition of
some of the tested compounds (10e14). Secondly, similar mecha-
nism of action of both oxacillin and cloxacillin is closely connected
with the PBP protein and differs from the mechanism of action of
other antibiotics used in the studies in vitro.
Docking results show that both oxacillin and cloxacillin ﬁt intoFig. 3. Visualization of oxacillin (orange) and cloxacilin (blue) docking to MecR1
binding site. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)the binding site of MecR1 close to Ser391 (Fig. 3). The comparison of
oxacillin binding mode to the binding mode of 12 (Fig. 4a) and the
binding mode of cloxacillin to the binding mode of 10 (Fig. 4b)Fig. 4. Comparison of docking results of oxacillin (orange) and 12 (blue) (a) and
cloxacillin (orange) and 10 (blue) (b) to MecR1. Ser391 is highlighted in red. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
Fig. 5. Snapshots of simulations of 12 (A), 13 (B, C) and oxacillin (D) from the ﬁrst (i), central (ii) and last (iii) frames of MD simulations. B refers to studies with starting pose of 13
with the lowest docking score, C e to starting pose of 13 analogous to 12.
Fig. 6. Snapshots of simulations of 10 (A) and cloxacillin (B) from the ﬁrst (i), central
A. Matys et al. / European Journal of Medicinal Chemistry 101 (2015) 313e325 319revealed that in case of both pair compounds, the parts of the latter
molecules that come into close proximity of Ser391 are parts of
aromatic rings in contrast to free methyl groups and oxygen atoms
from the ketone approaching Ser391 in the case of the antibiotic
molecules.
2.3.2. Molecular dynamics simulation
In vitro experiments showed that the compounds which
induced the greatest overcoming of antibiotic resistance were 10
and 12. They are structurally different from all compounds but one,
and that is 13. Therefore, these three compounds were selected for
further evaluation in molecular dynamics studies. Due to extremely
high similarity of the compounds 12 and 13, they were analyzed in
detail.
The compounds 12 and 13 are similar in topology. Nevertheless,
only 12 enhances oxacillin antibacterial activity in vitro. Molecular
dynamics simulation was performed for MecR1-12, MecR1-13 and
MecR1-oxacillin (for comparison) complexes in order to reveal
differences in interaction scheme of the compounds. All simula-
tions were conducted under the same conditions, with the starting
conformations of the compounds from their complexes with
MecR1 of the lowest values of docking score. As conformations with
the lowest values of docking score were slightly different for
compound 12 and 13, additional simulation for compound 13 was
run with the starting conformation analogous to the one of the
compound 12.
During the entire simulations (20 ns), both compounds 12
(Fig. 5) and 10 (Fig. 6) tend to stay in the entrance to the binding
cavity of the MecR1 sensor domain, similar to oxacillin and cloxa-
cillin which remain close to Ser391 (Figs. 5A and 6A). In contrast,
compound 13 leaves its initial position and locates nearby the
cavity in experiments with the starting pose with the lowest value(ii) and last (iii) frames of MD simulations.
A. Matys et al. / European Journal of Medicinal Chemistry 101 (2015) 313e325320of docking score (Fig. 5B) or ﬂips in a way that the moiety of
condensed aromatic rings does not block the entrance to the
binding cavity in experiments with the starting pose of 13 being
analogous to 12 (Fig. 5C). Both oxacillin and cloxacillin stay in the
proximity of the active site during the whole simulation (Figs. 5D
and 6B) (Fig. 7).2.4. Proliferation assay
The anti-proliferative effect of the active compound 12 against
mammalian cells was tested using HEK-293 cell line and a colori-
metric, commercial test EZ4U. A standard cytotoxic drug doxoru-
bicin was used as a positive control. The results of this assay are
presented in Fig. 7. Compound 12 did not exert any signiﬁcant anti-
proliferative effect against HEK-293 cell line: the viability of the
cells exposed to its 0.125 mM concentration (active against MRSA)
was 91 ± 7.67%. This makes the compound 12 a drug-like one and a
good candidate for further pre-clinical tests.2.5. SAR-discussion
The study describes an initial step in the search for new che-
mosensitizers of resistant Gram-positive pathogen MRSA in the
new chemical family of imidazolidin-4-one derivatives, which
could be helpful as “adjuvants” to increase antibiotic efﬁcacy.
Although the battle against resistant S. aureus is an important
therapeutic question, the number of studies providing successful
tools is not sufﬁcient, and these are predominantly focused onMDR
protein efﬂux pumps, especially NorA. Even though several families
of chemical compounds that are able to modulate NorA have been
described [10e16], it is difﬁcult to ﬁnd any lines of evidence which
suggest pharmacophore models, lead structures or any structural
requirements for chemosensitizers acting on other MDR proteins of
MRSA, such as PBP2a or MecR1. In the absence of appropriate data,
we selected representative imidazolidine-4-one derived com-
pounds (7e19) based on their promising chemosensitizing- and
efﬂux pump inhibitory properties against several strains of multi-
drug resistant Gram-negative bacteria [25]. The representative
group contains three common structural features: the imidazoli-
dine-4-one core, an aromatic fragment ending position 5 and an
amine terminal fragment substituted at 2- (group A) or 3-position
(groups B and C) of imidazolidine-4-one.
In the case of group A, the whole considered population of the
compounds (7e13) has the conserved core of 1H-imidazol-5(4H)-
one and free piperazine terminated fragment at position 2. The
compounds differ in their size and substituents of the aromatic
ring, which is placed within the 5-arylidene fragment, and this
difference seems to be crucial for their “co-operative” action with-10 -8 -6 -4 -2
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Fig. 7. Anti-proliferative effect of 12 against HEK-293 cell line. Values represent the
mean of n ¼ 4 experiments. DX stands for a positive control, doxorubicin.the antibiotics. The members of the group A were identiﬁed as the
most promising efﬂux pump inhibitors of tripartite efﬂux pumps in
Gram-negative bacteria in our previous studies (data under publi-
cation elsewhere). Here, the group also seems to be the most
interesting one because of the signiﬁcant action against the MRSA
HEMSA 5 strain that was observed for the members possessing
fused rings, especially naphthalen (10) and anthracen (12)
(Tables 1e5).
In the direct antibacterial activity test for the resistant MRSA
strain, the ﬂuorenylmethylidene derivative 11 as well as the phe-
nanthrenemethylidene one 13 displayed 23- (11) and 46-fold (13)
lower MIC than that of oxacillin, whereas their MIC in the case of
the reference strain was 4e32-fold higher than that of oxacillin. In
general, the compounds (11, 13) displayed direct antibacterial MIC
against the MRSA HEMSA 5 strain, lower than that of all the tested
b-lactam antibiotics and aminoglycoside neomycin (Table 2). These
results suggest potential antibiotic properties of the derivatives
with triple fused rings, particularly promising in the case of path-
ogenic MRSA strain that is resistant to b-lactam antibiotics. It is
worth emphasizing that all the derivatives with fused aromatic
rings (10e13), unlike the tested antibiotics, demonstrated only
slight (1e8 fold) increase of their MIC values when the reference
strain ATCC 25923 was replaced with the MRSA strain. In the same
situation, the MIC values of b-lactam antibiotics increased from
370-fold in the case of ampicillin with sulbactam to over 1500-fold
in the case of oxacillin and from 37- (ciproﬂoxacin) to 240-fold
(neomycin) in the case of other antibiotics tested (Table 2). It con-
ﬁrms the chemosensitizing properties of the piperazine arylide-
noimidazolones against pathogenic S. aureus.
The most potent antibacterial action is seen for the phenan-
threne derivative 13, but this compound did not show any ability to
increase efﬁcacy of all the tested antibiotics in both of the investi-
gated strains. In contrast, the b-naphthylmethylidene derivative 10
and the anthracenylmethylidene one (12) demonstrated very weak
direct antibacterial action in both of the tested strains of S. aureus
(Table 2), but they were able to improve efﬁcacy of oxacillin in the
MRSA HEMSA 5 strain 128- and 64-fold, respectively (Table 3). This
seems to be particularly interesting, especially when high struc-
tural similarities of the compounds 12 and 13, which differ only in
their triple-fused aromatic rings, are considered. The results indi-
cate that the linear ring system of naphthalen (10) and a bit more
branchy anthracene (12) favors restoration of b-lactam antibiotics
activity in the resistant MRSA strain, while this property disappears
with a slight twist of aromatic area in the case of the triple fused
system of the phenanthrene derivative (13).
On the basis of molecular modeling studies, we postulate that
the mechanism of action of 10 and 12 is connected with the MecR1
protein. Docking results show that 10 and 12 are likely to bind in
the region of entrance to the MecR1 active site. Thus, it can be
suggested that they prevent antibiotics from binding to the active
site of MecR1. Moreover, it seems that both 10 and 12 do not
interact with residues from the binding site of PBP2a, and therefore
the mechanism of their action through this protein is less probable.
In comparison, docking shows that oxacillin and cloxacillin are very
likely to interact with Ser391 of MecR1, which has also been proven
experimentally [29] and which in turn supports the reliability of
docking results.
The comparison of the binding modes of 12 and 13 reveals dif-
ferences in their interaction with MecR1. Compound 12 is more
likely to bind in the region of entrance to the binding site, while 13
locates in the upper part of the cavity, leaving free space in the
binding pocket and allowing oxacillin to bind. This may be the
reason why 12 is more effective, as it completely blocks the
entrance to binding site for oxacillin.
This hypothesis of the steric effect being the reason of activity of
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10 and 12 stay in the entrance to the binding cavity during the
whole simulation, preventing oxacillin or cloxacillin from coming
into the close proximity of Ser391 and activating MecR1. On the
other hand, compound 13moves from its initial position and leaves
space for oxacillin to interact with the active site of this protein and
induce the synthesis of PBP2a with lowered afﬁnity to b-lactam
antibiotics (when simulations were carried out taking the pose
with the lowest docking score) or ﬂips in a way that aromatic rings
are no longer preventing oxacilin from interaction with the active
site (which was proved in simulations started from pose of 13
analogous to 12).
Despite the intriguing chemosensitizing action of the arylide-
neimidazolones (10e13), the rest of the investigated compounds
did not demonstrate any expected pharmacological action in
S. aureus. Groups B and C (Table 1) represent lines of modiﬁcations
in which the imidazolidine-4-one core was enriched with a
carbonyl fragment at position 2 forming hydantoin. The basic dif-
ference between the groups A and B is observed in the length and
position of the amine terminal fragment, which has been moved
from position 2 to 3. The compounds (14e16) did not display any
antibacterial action in the tested concentration. However, a mod-
erate potency to increase efﬁcacy of cloxacillin in the MRSA strain
(8-fold) was observed for the methylpiperazine-propylamine de-
rivative 14. Apart from this one case, the piperazine derivatives of
the 5-arylidenehydantoin belonging to the group B (15, 16) were
inactive in all microbiological assays performed.
The results indicated that further chemical modiﬁcations (group
C), that replaced the 5-arylidene moiety with 5-naphthyl-5-methyl
ones and introduced primary amine at the end of 3-hydantoin
substituents, did not give the expected biological results. The
members of the group C (17e19) showed neither antibacterial nor
chemosensitizing action against both of the tested S. aureus strains
(Table 2, Table 3).
The results obtained from the evaluation in silico of the selected
compounds indicate that further structure modiﬁcations and
search for new compounds with similar mechanism of action
(blocking access of antibiotic to MecR1) should be oriented at
ﬁnding molecules with rigid bulky substituents. Nevertheless, the
size of the molecules cannot be increased unlimitedly so as their
ability to stay in the close proximity to theMecR1 binding site is not
lost.
3. Conclusions
The multidisciplinary studies performed here allowed us to
investigate chemosensitizing actions of three different groups of
amine derivatives of 5-aromatic imidazole-4-ones in the multidrug
resistant strain of S. aureus, MRSA HEMSA 5. According to the re-
sults obtained, the chemosensitizing properties were found for the
group of piperazine derivatives of 5-arylidene-3H-imidazol-4(5H)-
one (group A) whereas both primary amine derivatives of 5-
arylhydantoin and piperazine-alkyl derivatives of 5-
arylidenhydantoin were rather inactive. In the group A, the com-
pounds with fused aromatic rings showed resistance against MDR
mechanisms of MRSA HEMSA 5. Especially (Z)-5-(naphthalen-2-
ylmethylene)-2-(piperazin-1-yl)-3H-imidazol-4(5H)-one (10) and
(Z)-5-(anthracen-10-ylmethylene)-2-(piperazin-1-yl)-3H-imida-
zol-4(5H)-one (12) turned out to be the most promising com-
pounds. They were deprived of their direct antibacterial activity,
but were able to increase antibiotic effectiveness of b-lactam anti-
biotics (from 64 to 256-fold) against the MRSA strain. Furthermore,
two compounds, (Z)-5-((9H-ﬂuoren-2-yl)methylene)-2-(piper-
azin-1-yl)-3H-imidazol-4(5H)-one (11) and (Z)-5-(phenanthren-9-
ylmethylene)-2-(piperazin-1-yl)-3H-imidazol-4(5H)-one (13),demonstrated signiﬁcant antibacterial properties against the MRSA
strain, but they did not improve efﬁcacy of all the considered an-
tibiotics (b-lactams, aminoglycosides, ﬂuoroquinolones) against
the investigated S. aureus pathogens.
Molecular modeling, which involved docking studies and mo-
lecular dynamics, indicated that the most probable mechanisms of
chemosensitizing actions of the considered compounds are the
interactions with the MecR1 protein, whereas their inﬂuence on
PBP2a is rather unlikely. The computational studies allowed us to
postulate some hypotheses to explain the ability of both the
naphthylmethylidene (10) and the anthracylmethylidene (12) de-
rivatives to improve efﬁcacy of b-lactam antibiotics against the
MRSA strain as well as the lack of the activity in the case of phe-
nanthrenemethylidene derivative 13with high structural similarity
to 12. Both docking studies and molecular dynamics indicated that
the compounds 10 and 12 prevent antibiotics from binding to the
active site of MecR1 while the compound 13 is able to leave free
space in the binding pocket allowing oxacillin to bind. Although the
hypotheses come from theoretical considerations, they seem to be
of great importance for further experimental studies on the
mechanism of anti-MDR actions of 5-arylideneimidazolones
against the MRSA strains. In silico results suggest that the
possible mechanism of action of the active compounds found in the
study is connected with the inhibition of MecR1 activation through
blocking of the entrance to the MecrR1 binding cavity and pre-
venting the antibiotics from binding. Although the requirements
for compounds that are supposed to act through this mechanism
resulting from in silico studies are relatively simple (rigid, bulky
substituents), their interactionwith MecR1 will have to be carefully
analyzed, as shown by the example of the two compounds with
fused aromatic rings that are very similar, but only one of them is
able to successfully overcome antibiotic resistance in MRSA.
The most important achievement of the work is the identiﬁca-
tion of new active chemosensitizers, compounds 10 and 12, with
high capacity to increase antibiotics efﬁcacy of oxacillin and clox-
acillin against the resistant MRSA strain. The compounds can be a
good lead structure in further search for tools to combat bacterial
multidrug resistance as well as promising candidates (12) for
further pre-clinical tests considering their negligible toxic effects in
the proliferation assay performed here.
4. Experimental
4.1. Chemistry
NMR spectra were recorded on a Varian Mercury VX 300 MHz
PFG instrument (Varian Inc., Palo Alto, CA, USA) in DMSO-d6 at
ambient temperature using the solvent signal as an internal stan-
dard (300 MHz for 1H and 75 MHz for 13C). Melting points were
determined using Mel-Temp II apparatus and are uncorrected.
Elemental analyses were within ±0.4% of the theoretical values
unless stated otherwise. LC/MS spectra were measured using the
Waters ACQUITY UPLC system (Waters Corporation, Milford, MA,
USA) connected to a mass spectrometer Waters TQD (electrospray
ionization (ESI), double quadrupole). Synthesis of the ﬁnal com-
pounds 7e14 and 5-arylidenehydantoin intermediates (20, 21) has
been described elsewhere [25e27,30].
4.1.1. General procedure for the preparation of the N3-oxiran-5-
arylidene-imidazolidine-2,4-dione intermediates (22, 23)
5-arylideneimidazolidine-2,4-diones (20, 21), obtained based
on the method described previously [25], were used. 2,3-Epoxy-1-
propanol (0.015 mol, 1.11 g) was solved in DMF (50 mL) and cooled
down to 0 C in an ice bath while being stirred. Then the 5-
arylideneimidazolidine-2,4-dione (20, 21) (0.01 mol) and
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the reactants had dissolved. The solution of diethyl azodicarbox-
ylate DEAD (0.01 mol, 1.74 g) in dry DMF (10 mL) was added to the
mixture dropwise and stirring was continued at room temperature
for further 4 h. Then, the mixture was poured into 200 mL of water
to precipitate and left at 0e4 C overnight. After ﬁltration, the
precipitate was washed with water and diethyl ether. A pure
product (22 or 23) was obtained from the precipitate by column
chromatography with CH2Cl2/acetone (17:3).4.1.1.1. (Z)-5-(4-chlorobenzylidene)-3-(oxiran-2-ylmethyl)imidazoli-
dine-2,4-dione (22).
(Z)-5-(4-chlorobenzylidene)imidazolidine-2,4-dione (20)
(0.01 mol, 2.23 g) was used. Yield 0.79 g, 28%; mp: 196e200 C. LC/
MS: purity: 95%, tR ¼ 5.64, (ESI) m/z [M þ Hþ] 279.17. 1H NMR
(DMSO-d6): d 2.69 (dd, J1 ¼ 4.87 Hz, J2 ¼ 2.57 Hz, 1H, oxiran),
2.83e2.86 (m,1H, oxiran), 3.23e3.29 (m,1H, oxiran), 3.76e3.89 (m,
2H, alkyl), 6.72 (s, 1H, CH]C), 7.38e7.44 (m, 4H, Ar), 8.86 (s, 1H,
N1H).4.1.1.2. (Z)-5-(2,4-dichlorobenzylidene)-3-(oxiran-2-ylmethyl)imida-
zolidine-2,4-dione (23).
(Z)-5-(2,4-dichlorobenzylidene)imidazolidine-2,4-dione (21)
(0.01 mol, 2.57 g) was used. Yield 0.53 g, 17%; mp: 185e190 C. LC/
MS: purity: 98%, tR ¼ 5.99, (ESI) m/z [M þ Hþ] 313.07. 1H NMR
(DMSO-d6): d 2.52e2.55 (m, 1H, oxiran), 2.71e2.74 (m, 1H, oxiran),
3.14e3.16 (m, 1H, oxiran), 3.62e3.64 (d, J ¼ 4.7 Hz, 2H, alkyl), 6.53
(s, 1H, CH]C), 7.44e7.47 (dd, J1¼8.4 Hz, J2¼ 2.3 Hz,1H, Ar), 7.69 (s,
1H, Ar), 7.78e7.81 (d, J ¼ 8.5 Hz, 1H, Ar), 11.06 (br.s, 1H, N1H).4.1.2. Procedures for the preparation of the 3-(3-(4-acetylpiperazin-
1-yl)-2-hydroxypropyl)-5-arylideneimidazolidine-2,4-diones (24,
25)
4.1.2.1. (Z)-3-(3-(4-acetylpiperazin-1-yl)-2-hydroxypropyl)-5-(4-
chlorobenzylidene)-imidazolidine-2,4-dione (24).
(Z)-5-(4-chlorobenzylidene)-3-(oxiran-2-ylmethyl)imidazolidine-
2,4-dione (22) (2.3 mmol, 0.65 g), 1-acetylpiperazine (3.3 mmol,
0.42 g) were irradiated at 450W for 3 min, then at 600W for 4 min
and then at 750 W for 26 min (2  5 min, 2 min, 14 min) in a
standard household microwave oven. The obtained glassy residue
was puriﬁed by crystallization with methanol. Yield 0.60 g, 64%;
mp: 188e192 C. LC/MS: purity: 99%, tR ¼ 3.46, (ESI) m/z [M þ Hþ]
407.27. 1H NMR (DMSO-d6): d 1.93 (s, 3H, CH3), 2.26e2.43 (m, 6H,
alkyl, Pip), 3.34e3.39 (m, 4H, Pip), 3.47e3.50 (m, 2H, alkyl),
3.92e3.96 (m, 1H, CHOH), 4.96e4.98 (d, J ¼ 5.38 Hz, 1H, OH), 6.49
(s, 1H, CH]C), 7.41e7.46 (m, 2H, Ar), 7.61e7.66 (m, 2H, Ar), 10.79 (s,
1H, N1H).4.1.2.2. (Z)-3-(3-(4-acetylpiperazin-1-yl)-2-hydroxypropyl)-5-(2,4-
dichloro-benzylidene)imidazolidine-2,4-dione (25).
(Z)-5-(2,4-dichlorobenzylidene)-3-(oxiran-2-ylmethyl)imidazoli-
dine-2,4-dione (23) (0.64 mmol, 0.2 g) was melted with 1-
acetylpiperazine (1.28 mmol, 0.16 g) by using an oil bath at tem-
perature of 160 C for 30 min. The obtained glassy residue was
puriﬁed by crystallization with methanol and activated charcoal.
Yield 0.15 g, 55%; mp: 190e195 C. LC/MS: purity: 100%, tR ¼ 4.03,
(ESI) m/z [M þ Hþ] 441.31. 1H NMR (DMSO-d6): d 1.93 (s, 3H, CH3),
2.26e2.43 (m, 6H, alkyl, Pip), 3.30e3.38 (m, 4H, Pip), 3.47e3.50 (m,
2H, alkyl), 3.92e4.00 (m,1H, CHOH), 4.96e4.99 (m,1H, OH), 6.54 (s,
1H, CH]C), 7.46e7.50 (m, 1H, Ar), 7.68 (s, 1H, Ar), 7.73e7.70 (m,1H,
Ar), 10.89 (s, 1H, N1H).4.1.3. General procedure for the preparation of the ﬁnal 5-
arylidene3-(2-hydroxy-3-(piperazin-1-yl)- propyl)-imidazolidine-
2,4-diones (15, 16)
The 3-(3-(4-acetylpiperazin-1-yl)-2-hydroxypropyl)-5-
arylideneimidazolidine-2,4-dione (24, 25) (0.25e1 mmol) was
boiled in 15% HCl (1.5e2 mL) for 45e180 min, thus producing the
hydrochloride form of the ﬁnal deprotected piperazine derivatives
(15, 16).
4.1.3.1. (Z)-5-(4-chlorobenzylidene)-3-(2-hydroxy-3-(piperazin-1-
yl)- propyl)-imidazolidine-2,4-dione hydrochloride (15).
(Z)-3-(3-(4-acetylpiperazin-1-yl)-2-hydroxypropyl)-5-(4-
chlorobenzylidene)imidazoli-dine-2,4-dione (24) (1 mmol, 0.41 g)
was boiled in 2 mL of 15% HCl for 180 min. Yield 0.41 g, 100%; mp:
299e301.5 C. Anal. Calcd for C17H21ClN4O3HCl 2H2O: C, 46.69;
H, 5.82; N, 12.81; found: C, 46.73; H, 544; N, 12.60. 1H NMR (DMSO-
d6): d 2.96e3.25 (m, 8H, Pip), 3.40e3.73 (m, 4H, Pip), 4.21 (m, 1H,
CHOH), 5.95 (br.s, 1H, OH), 6.51 (s, 1H, CH]C), 7.44e7.47 (m, 2H,
Ar), 7.65e7.67 (m, 2H, Ar), 9.51 (br.s, 2H, NH2þ), 10.88 (s, 1H, N1H).
13C NMR (DMSO-d6): d 164.68, 155.58, 133.42, 133.29, 131.53, 129.25
127.76, 108.27, 63.45, 59.11, 42.62.
4.1.3.2. (Z)-5-(2,4-dichlorobenzylidene)-3-(2-hydroxy-3-(piperazin-
1-yl) propyl)imidazolidine-2,4-dione hydrochloride (16).
(Z)-3-(3-(4-acetylpiperazin-1-yl)-2-hydroxypropyl)-5-(2,4-
dichlorobenzylidene)imida-zolidine-2,4-dione (25) (0.25 mmol,
0.11 g) was boiled in 1.5 mL of 15% HCl for 45 min. Evaporation of
water gave white crystals of 16. Yield 0.066 g, 61%; mp:
267.8e271.2 C. Anal. Calcd for C17H20Cl2N4O3HCl 3H2O: C,
41.69; H, 5.56; N, 11.44; found: C, 41.3; H, 5.39; N, 11.25. 1H NMR
(DMSO-d6): d 3.20e3.56 (m, 12H, Pip, alkyl), 4.22 (br.s., 1H, CHOH),
5.95 (br.s, 1H, OH), 6.56 (s, 1H, CH]C), 7.46e7.50 (dd, J1 ¼ 8.4 Hz,
J2 ¼ 2.2 Hz, 1H, Ar), 7.69 (s, 1H, Ar), 7.73e7.70 (m, 1H, Ar), 9.47 (br.s,
2H, NH2þ), 11.00 (s, 1H, N1H). 13C NMR (DMSO-d6): d 164.40, 155.77,
134.41, 133.83, 131.61, 130.42, 130.06, 129.63, 128.16, 102.96, 64.22,
62.93, 54.04, 53.61, 49.06, 44.08.
4.1.4. Preparation of 5-methyl-5-(naphthalen-1-yl)imidazolidine-
2,4-dione (26)
The solution of ammonium carbonate (0.50 mol, 48.05 g) and
potassium cyanate (0.25 mol, 16.28 g) in 200 mL of water was
added to 1-acetonaphtone (0.1 mol, 15.2 mL) in 200 mL of ethanol.
The mixture was stirred at 55 C for 10 days, then densiﬁed in
vacuo, cooled and acidiﬁed to pH~5 with 35% solution of HCl. The
resulting solid was ﬁltrated and crystallized from EtOH. Yield
20.14 g, 84%; mp: 213e215 C. Anal. calcd. for C14H12N2O2: C, 69.99;
H, 5.03; N, 11.66; found C, 69.88; H, 4.99; N, 11.73. 1H NMR (DMSO-
d6): d 1.90 (s, 3H, CH3), 7.48e7.58 (m, 3H, Ar), 7.69e7.72 (dd,
J1 ¼7.4 Hz, J2 ¼ 1.0 Hz, 1H, Ar), 7.84e7.88 (m, 1H, Ar), 7.94e8.00 (m,
2H, Ar), 8.55 (s, 1H, N1H), 11.11 (br. s, 1H, N3H). 13C NMR (DMSO-d6):
d 26.7, 64.7, 124.1, 125.4, 126.1, 126.7, 126.9, 129.8, 130.2, 131.1, 134.1,
134.5, 156.8, 178.6.
4.1.5. General procedure for the preparation of 3-bromoalkyl-5-
methyl-5-(naphthalen-1-yl)imidazolidine-2,4-diones (27e29)
A mixture of 5-methyl-5-(naphthalen-1-yl)imidazolidine-2,4-
dione 26 (20 mmol, 4.81 g), potassium carbonate (60 mmol,
8.29 g) and triethylbenzylammonium chloride (TEBA, 3 mmol,
0.68 g) in 100 mL of acetone was stirred at room temperature for
15 min. Subsequently, the solution of an appropriate dibro-
moalkane (20 mmol) in acetone (20 mL) was added and the
mixture was stirred for 30 min at room temperature, then reﬂuxed
for 1 h. After ﬁltration, the solvent was removed in vacuo and the
resulting crude was puriﬁed by column chromatography.
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dine-2,4-dione (27). Yield 3.94 g, 55%; mp: 142e143 C. Anal. calcd.
for C17H17BrN2O2: C, 56.52; H, 4.74; N, 7.75; found C, 56.45; H, 4.69;
N, 7.71. 1H NMR (DMSO-d6): d 1.91 (s, 3H, CH3), 2.13e2.23 (m, 2H,
alkyl), 3.55 (t, J ¼ 7.0 Hz, 2H, alkyl), 3.63 (t, J ¼ 6.6 Hz, 2H, alkyl),
7.49e7.56 (m, 3H, Ar), 7.64e7.68 (m, 1H, Ar), 7.72e7.75 (dd,
J1 ¼ 7.4 Hz, J2 ¼ 1.0 Hz, 1H, Ar), 7.95e8.00 (m, 2H, Ar), 8.92 (s, 1H,
N1H). 13C NMR (DMSO-d6): d 26.5, 31.3, 32.0, 37.4, 63.5, 123.9, 125.5,
126.2, 126.9, 129.9, 130.4, 130.9, 133.7, 134.5, 156.1, 176.9.
4.1.5.2. 3-(4-Bromobutyl)-5-methyl-5-(naphthalen-1-yl)imidazoli-
dine-2,4-dione (28). Yield 4.29 g, 57%; mp: 101e103 C. Anal. calcd.
for C18H19BrN2O2: C, 57.61; H, 5.10; N, 7.47; found: C, 57.77; H, 5.34;
N, 7.38. 1H NMR (DMSO-d6): d 1.73e1.88 (m, 4H, alkyl), 1.90 (s, 3H,
CH3), 3.53e3.61 (m, 4H, alkyl), 7.49e7.56 (m, 3H, Ar), 7.67e7.75 (m,
2H, Ar), 7.95e8.00 (m, 2H, Ar), 8.89 (s, 1H, N1H). 13C NMR (DMSO-
d6): d 26.7, 26.8, 30.2, 34.9, 37.8, 63.5, 124.0, 125.5, 126.2, 126.9,
129.8, 130.3, 131.0133.7, 134.5, 156.3, 176.9.
4.1.5.3. 3-(5-Bromopentyl)-5-methyl-5-(naphthalen-1-yl)imidazoli-
dine-2,4-dione (29). Yield 4.29 g, 55%; mp: 102e104 C. Anal. calcd.
for C19H21BrN2O2: C, 58.62; H, 5.44; N, 7.20; found: C, 58.47; H,
5.62; N, 7.19. 1H NMR (DMSO-d6): d 1.38e1.48 (m, 2H, alkyl),
1.60e1.70 (m, 2H, alkyl), 1.78e1.87 (m, 2H, alkyl), 1.90 (s, 3H, CH3),
3.50 (t, J ¼ 6.5 Hz, 4H, alkyl), 7.49e7.55 (m, 3H, Ar), 7.68e7.74 (m,
2H, Ar), 7.95e8.01 (m, 2H, Ar), 8.88 (s, 1H, N1H). 13C NMR (DMSO-
d6): d 25.3, 26.7, 27.1, 32.2, 35.4, 38.3, 63.5, 124.1, 125.5, 126.2, 126.9,
129.8, 130.3, 130.9, 133.8, 134.5, 156.3, 176.9.
4.1.6. General procedure for the preparation of phthalimide
derivatives (30e32)
A mixture of potassium phtalimide (5 mmol, 0.93 g), potassium
carbonate (15 mmol, 2.07 g) and TEBA (0.75 mmol, 0.17 g) in
12.5 mL of acetone was stirred at room temperature for 30 min.
Subsequently, the solution of an appropriate bromide 27e29
(5 mmol) in 12.5 mL of acetone was added and the mixture was
reﬂuxed for 2 h. After ﬁltration, the solvent was removed in vacuo
and the resulting crude was puriﬁed by column chromatography.
4.1.6.1. 2-(3-(5-methyl-5-(naphthalen-1-yl)-2,4-dioxoimidazolidin-
1yl)propyl)isoindoline-1,3-dione (30). Yield 1.62 g, 76%; mp:
204e205 C. Anal. calcd. for C25H21N3O4: C, 70.25; H, 4.95; N, 9.83;
found: C, 70.46; H, 5.16; N, 9.89. 1H NMR (DMSO-d6): d 1.93 (s, 3H,
CH3), 1.97e2.04 (m, 2H, alkyl), 3.57e3.68 (m, 4H, alkyl), 7.49e7.59
(m, 3H, Ar), 7.67 (dd, J1 ¼ 7.4 Hz, J2 ¼ 1.0 Hz, 1H, Ar), 7.73 (dd,
J1 ¼7.4 Hz, J2 ¼ 1.0 Hz, 1H, Ar), 7.79e7.88 (m, 4H, Ar), 7.95e8.00 (m,
2H, Ar), 8.91 (s, 1H, N1H); 13C NMR (DMSO-d6): d 26.6, 27.2, 35.8,
36.5, 63.6123.5, 123.5, 124.0, 125.5, 126.2, 126.9, 127.1, 129.8, 130.4,
131.0132.1, 132.1, 133.6, 134.5, 134.8, 134.8, 156.1, 168.3, 176.8.
4.1.6.2. 2-(3-(5-methyl-5-(naphthalen-1-yl)-2,4-dioxoimidazolidin-
1-yl)butyl)isoindoline-1,3-dione (31). Yield 1.76 g, 80%; mp:
160e162 C. Anal. calcd. for C26H23N3O4: C, 70.73; H, 5.25; N, 9.52;
found: C, 70.43; H, 5.35; N, 9.92. 1H NMR (DMSO-d6): d 1.65 (m, 4H,
alkyl), 1.89 (s, 3H, CH3), 3.54 (t, J ¼ 6.6 Hz, 2H, alkyl), 3.64 (t,
J ¼ 6.6 Hz, 2H, alkyl), 7.48e7.53 (m, 3H, Ar), 7.62e7.65 (m, 1H, Ar),
7.71 (dd, J1 ¼ 7.4 Hz, J2 ¼ 1.0 Hz, 1H, Ar), 7.81e7.89 (m, 4H, Ar),
7.94e7.99 (m, 2H, Ar), 8.85 (s, 1H, N1H). 13C NMR (DMSO-d6): d 25.6,
25.9, 26.6, 37.5, 38.1, 63.5, 123.5, 123.5, 123.9, 125.5, 126.1, 126.8,
126.9, 129.8, 130.3, 130.9, 132.0, 132.0, 133.6, 134.5, 134.9, 134.9,
156.3, 168.5, 176.9.
4.1.6.3. 2-(3-(5-methyl-5-(naphthalen-1-yl)-2,4-dioxoimidazolidin-
1-yl)butyl)isoindoline-1,3-dione (32). Yield 1.92 g, 84%; mp:
145e146 C; Anal. calcd. for C27H25N3O4: C, 71.19; H, 5.53; N, 9.22;found C, 71.36; H, 5.58; N, 9.44. 1H NMR (DMSO-d6): d 1.30e1.38 (m,
2H, alkyl), 1.59e1.67 (m, 4H, alkyl), 1.85 (s, 3H, CH3); 3.47e3.58 (m,
4H, alkyl), 7.48e7.54 (m, 3H, Ar), 7.64e7.72 (m, 2H, Ar), 7.79e7.87
(m, 4H, Ar), 7.94e8.00 (m, 2H, Ar), 8.83 (s, 1H, N1H). 13C NMR
(DMSO-d6): d 24.1, 26.6, 27.7, 28.1, 37.7, 38.3, 63.5, 123.4, 123.4124.0,
125.5,126.2,126.8,126.9,129.8,130.3130.9,132.0,132.1,133.0,133.7,
134.5, 134.8, 156.3, 168.4, 176.8.
4.1.7. General procedure for the preparation of primary amines
(17e19)
A mixture of the appropriate phtalimide derivative 30e32
(2 mmol) and hydrazine monohydrate (20 mmol, 1.56 mL) in 20 mL
of ethanol was reﬂuxed for 2.5 h. After ﬁltration and evaporation of
the solvent in vacuo, the resulting crudewas reﬂuxed with 30mL of
10% HCl for 15 min and again ﬁltrated. The ﬁltrate was then alkal-
ized with 15% solution of NaOH and extracted with dichloro-
methane (2  30 mL). The combined organic layers were dried and
concentrated in vacuo. The product was puriﬁed by column
chromatography.
4.1.7.1. 3-(3-Aminopropyl)-5-methyl-5-(naphthalen-1-yl)imidazoli-
dine-2,4-dione (17). Yield 0.382 g, 64%; mp: 62e63C. Anal. calcd.
for C17H19N3O2: C, 68.67; H, 6.44; N, 14.13; found: C, 68.85; H, 6.69;
N, 14.09. 1H NMR (DMSO-d6): d 1.66e1.75 (m, 2H, alkyl), 1.91 (s, 3H,
CH3), 2.58 (t, J ¼ 6.2 Hz, 2H, alkyl), 3.56 (t, J ¼ 6.6 Hz, 2H, alkyl),
7.50e7.55 (m, 3H, Ar), 7.63e7.75 (m, 2H, Ar), 7.95e8.02 (m, 2H, Ar).
13C NMR (DMSO-d6): d 26.7, 31.7, 36.4, 39.1, 63.5, 124.1, 125.5, 126.2,
126.9, 126.9, 129.8, 130.3, 131.0133.7, 134.5, 156.4, 177.0.
4.1.7.2. 3-(4-Aminobutyl)-5-methyl-5-(naphthalen-1-yl)imidazoli-
dine-2,4-dione (18). Yield 0.376 g, 60%;mp: 191e194 C. Anal. calcd.
for C18H21N3O2: C, 69.43; H, 6.80; N, 13.49; found: C, 69.20; H, 6.90;
N, 13.21. 1H NMR (DMSO-d6): d 1.35e1.45 (m, 2H, alkyl), 1.59e1.69
(m, 2H, alkyl), 1.90 (s, 3H, CH3), 2.56 (t, J ¼ 7.0 Hz, 2H, alkyl), 3.49 (t,
J ¼ 7.0 Hz, 2H, alkyl), 7.49e7.55 (m, 3H, Ar), 7.67e7.75 (m, 2H, Ar),
7.95e8.00 (m, 2H, Ar). 13C NMR (DMSO-d6): d 25.5, 26.7, 29.8, 38.5,
39.1, 63.5, 124.1, 125.5, 126.2, 126.9, 126.9, 129.8, 130.3, 131.0133.7,
134.5, 156.3, 176.9.
4.1.7.3. 3-(5-Aminopentyl)-5-methyl-5-(naphthalen-1-yl)imidazoli-
dine-2,4-dione (19). Yield 0.412 g, 63%; mp: 134e136 C. Anal.
calcd. for C19H23N3O2: C, 70.13; H, 7.12; N, 12.91; found: C, 70.16; H,
7.39; N, 12.72. 1H NMR (DMSO-d6): d 1.32e1.42 (m, 4H, alkyl),
1.57e1.66 (m, 2H, alkyl), 1.90 (s, 3H, CH3), 2.47e2.53 (m, 2H, alkyl),
3.48 (t, J ¼ 6.9 Hz, 2H, alkyl), 7.45e7.55 (m, 3H, Ar), 7.68e7.74 (m,
2H, Ar), 7.95e8.00 (m, 2H, Ar). 13C NMR (DMSO-d6): d 24.2, 26.7,
27.9, 32.9, 38.6, 41.7, 63.5, 124.1, 125.5, 126.2, 126.8, 126.9, 129.8,
130.3, 131.0133.8, 134.5, 156.3, 176.9.
4.2. Molecular modeling methods
Crystal structures of PBP2a (PDB ID: 1VQQ) and binding domain
of MecR1 (PDB ID: 2IWB) were fetched from the PDB database [31].
Three-dimensional conformations of all newly synthesized com-
pounds, cloxacillin and oxacillin were generated using LigPrep [32]
from Schr€odinger Suite 2013. All molecules were generated in
protonation states at pH 7 ± 2 using OPLS_2005 force ﬁeld [33]. The
compoundswere docked into the binding sites of MecR1 and PBP2a
using Schr€odinger Glide in extra precision mode (maximum 5
poses for each instance from Ligprep were enabled).
For the compounds 10, 12, 13, cloxacillin and oxacillin (for
comparison) molecular dynamic simulation studies were per-
formed. The simulations were carried out using Schr€odinger Des-
mond [34]. Protein structure was preprocessed and optimized in
Schr€odinger Protein Preparation Wizard [35e37]. The system was
A. Matys et al. / European Journal of Medicinal Chemistry 101 (2015) 313e325324composed of protein, chemical compound and solvent (TIP3P
model of water). The input poses for MD were obtained from
docking and complexes with the best docking scores were selected;
as conformations of 12 and 13 for the ligand-protein complexes
were slightly different, 13 underwent additional simulation with
the analogous starting conformation as 12. The aim of this proce-
dure was to check whether the obtained ligand-protein complexes
are stable. Each simulation lasted for 20 ns, and was performed
using OPLS_2005 force ﬁeld.
4.3. Microbiological assays
The assays aimed to determine the increase of antibiotic efﬁcacy
were conducted by determining if/to what extent the compounds
reduce the minimum inhibitory concentrations of oxacillin, cloxa-
cillin, ampicillin/sulbactam, ciproﬂoxacin and neomycin by means
of a serial dilution broth microplate method according to the CLSI
requirements [28].
Serial two-fold dilutions of oxacillin (SigmaeAldrich; cat. no.
28221), cloxacillin (SigmaeAldrich; cat. no. C9393), ampicillin/
sulbactam ratio 2:1 (SigmaeAldrich; cat. no. A9518, Sigma-
eAldrich; cat. no. S9701), ciproﬂoxacin (SigmaeAldrich; cat. no.
17850) or neomycin (Fagron; cat. no.113374) were prepared in 65 ml
of the Mueller-Hinton broth (Merck; cat. no. 1102930500). Suitable
concentrations of the compounds (not exceeding ¼ of their MICs;
total volume 10 ml) were then added. Bacterial suspensions were
diluted to OD ¼ 0.5. The resulting suspensions were then diluted
1:100 and added in the volume of 75 ml into the oxacillin serial
dilutions with the compounds. The results were read after 20-h
incubation at 37 C.
4.4. Proliferation assay
In vitro proliferation assay was conducted using HEK-293 cell
line and a commercial kit EZ4U (cat. no.: BI-5000, Biomedica)
containing uncolored tetrazolium salt that is reduced by living cells
into intensely colored formazan derivative. HEK-293 cell line was
cultured in Dulbecco's Modiﬁed Eagle's complete growth Medium
(DMEM) containing 10% fetal bovine serum (FBS), 100 mg/mL
streptomycin and 100 U/mL penicillin. The cells were cultured at
37 C in an atmosphere containing 5% CO2. The cells were seeded in
96-well plates at a concentration of 1.5  104 cells/well in 200 ml
culture medium and incubated for 24 h at 37 C and 5% CO2 to reach
60% conﬂuence. Next, the compound 12 was added into the
microplate at the ﬁnal concentrations 0.01e250 mM. The cells were
incubated with the compound for 48 h at 37 C and 5% CO2. Then,
20 ml of EZ4U labeling mixture was added and the cells were
incubated for 5 h under the same conditions. The absorbance of the
samples was measured using a microplate reader (PerkinElmer) at
492 nm. The activity of the standard drug doxorubicin (DX) was
estimated at the concentrations 0.005e100 mM as we described
previously [38]. All experiments were conducted in four repeti-
tions. GraphPad Prism 5.01 software was used to calculate the
experimental IC50 values.
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